#USA #New York #Class Action #Gross Law Firm #Altimmune

Important Notice for Altimmune, Inc. Shareholders

In a recent announcement, The Gross Law Firm has reached out to shareholders of Altimmune, Inc. (NASDAQ: ALT), particularly those who acquired shares during the specified class period. The law firm is urging these individuals to connect with them before the critical deadline of October 6, 2025, to explore their rights and potential lead plaintiff status in a class action lawsuit, which could offer compensation for losses incurred due to misleading information from the company.

This law firm's notice comes following serious allegations made against Altimmune regarding its Phase 2b clinical trial of Pemvidutide for the treatment of MASH (Metabolic Associated Steatotic Liver Disease). The trial’s topline results, announced on June 26, 2025, showed a disappointing lack of statistical significance in achieving its primary endpoint of fibrosis reduction. The press release revealed that, despite an attempted emphasis on positive trends in fibrosis improvement, a considerable placebo response hindered the expected outcomes.

As the company had generated high expectations leading up to these results, shareholders experienced a drastic impact once the market reacted to the news. The stock price significantly plummeted from a closing price of $7.71 per share on June 25, 2025, to just $3.61 on June 26, marking a staggering 53.2% decline in a single day.

The Gross Law Firm underscores that shareholders do not need to be appointed as lead plaintiffs to partake in any potential recovery from losses. Those who register will benefit from monitoring services, which will keep them informed as the case progresses, including updates on court-related developments. The firm takes pride in its commitment to protecting the rights of investors and ensuring responsible business practices among corporations.

Why This Timing Matters

For Altimmune shareholders, this isn't just a legal technicality; it’s a chance to reclaim their investment losses stemming from what the firm characterizes as deceptive practices by the company. The imminent deadline highlights the urgency for shareholders who have seen their investments diminished to act swiftly. Anyone who acquired shares during the class period from August 10, 2023, to June 25, 2025, is encouraged to seize this opportunity to register their damages and assert their rights.

Once registered with The Gross Law Firm, shareholders will be enrolled in an ongoing monitoring system that informs them about important milestones in the case, enabling them to stay informed and involved. Importantly, participating in this class action poses no financial risk to those wishing to explore their options for recovery.

Contact Information

Shareholders wishing to learn more or participate in this class action lawsuit should use the following contact methods:

• - Email: [email protected]
• - Phone: 646-453-8903
• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY 10018

With a mission dedicated to empowering investors and ensuring accountability within corporations, The Gross Law Firm maintains that shareholders deserve transparency and recourse whenever deceptive business practices compromise their investments. Shareholders of Altimmune, Inc. are therefore urged to act before the deadline approaches swiftly, ensuring their legal position is fortified amidst these challenging developments.